Results 191 to 200 of about 447,577 (315)
Estimated Glomerular Filtration Rate, Nutritional Factors, and Their Relationships With Homocysteine in Community-Dwelling Older Adults. [PDF]
Li HL, Chuang YM, Huang PJ, Chang PS.
europepmc +1 more source
This study presents a surfaceome‐reprogramming strategy for mutation‐independent lung cancer therapy by repurposing dexamethasone to prime mesenchymal stem cell‐derived nanovesicles. The engineered vesicles leverage multi‐valent interactions mediated by upregulated adhesion proteins, EPHA2, and NOTCH3.
Geunhye Kim +8 more
wiley +1 more source
Molecular Subtyping Based on EGFR Mutation-Associated Genes and the Prognostic Role of TRAF2 in Lung Adenocarcinoma. [PDF]
Gao B, Dong Z, Yan T, Liu Z, Chen J.
europepmc +1 more source
Designer Dynamic DNA Nanoaggregate in Living Cell for Mitochondrial Energy Restriction
This study presents the Tech‐tetrahedron, a designer dynamic DNA nanoaggregate engineered for precise mitochondrial energy restriction. Its trinity‐functionalized design integrates navigable unit, telomerase‐activated latch, and self‐assembly module.
Ruijia Deng +12 more
wiley +1 more source
Identifying potential inhibitors for wild-type EGFR tyrosine kinase through a cross-talk pathway strategy and an in-silico drug repurposing method. [PDF]
Abdelmalek D +5 more
europepmc +1 more source
Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
Valentina Mazza,1 Federico Cappuzzo1,2 1Department of Oncology-Hematology, 2Department of Medical Oncology, AUSL Romagna, Ravenna, Italy Abstract: The discovery of mutations in EGFR significantly changed the treatment paradigm of patients with EGFR ...
Cappuzzo F, Mazza V
core
We introduced genetically encodable, receptor‐independent nanobody‐CPP chimeras, termed endobodies, as robust and modular membrane protein degraders. Additionally, proteasome‐targeting domain (PTD)‐tethered endobody demonstrates further enhanced degradation potency.
Chengjian Zhou +3 more
wiley +1 more source
Targeting the ELF1/EGFR/ERK positive feedback loop overcomes resistance to androgen receptor inhibition in AR-Vs positive prostate cancer. [PDF]
Zhou M +11 more
europepmc +1 more source
Background. Primary and acquired resistance to selective Epidermal growth factor receptor (EGFR) inhibitors remains the most significant obstacle to the success of these targeted agents in cancer therapy.
Rosa, Roberta
core
This study introduces a biomimetic “nanofusion” platform that integrates the biostability of threose nucleic acids (TNA) with homotypic cell‐membrane cloaking to combat drug‐resistant TNBC. By leveraging a non‐canonical membrane‐fusion pathway for direct cytosolic delivery, the platform bypasses endosomal sequestration. To achieve potent AKT2 silencing
Wei Zheng +7 more
wiley +1 more source

